New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the first patient dosing in a Phase I trial for AC0176, an orally bioavailable chimeric degrader molecule targeting the androgen receptor protein. This marks a significant milestone in the development of innovative treatments for prostate cancer.
AC0176: Pre-Clinical Results
Pre-clinical studies have shown that AC0176, the first of its kind to be approved for clinical trials in the US and China, effectively and selectively degrades androgen receptor proteins. The molecule has demonstrated a broad-spectrum response to multiple androgen receptor mutations, along with good pharmacological properties and robust anti-tumor activity in animal tumor models.
Phase I Study Design
The Phase I study (NCT05673109) is designed to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0176 in patients with metastatic castration-resistant prostate cancer in China. This study will provide crucial data on the drug’s potential as a novel treatment option for this challenging form of cancer.
Strategic Implications
The initiation of the Phase I trial for AC0176 highlights Accutar Biotechnology’s commitment to advancing innovative therapies for prostate cancer. By targeting the androgen receptor, AC0176 has the potential to address significant unmet medical needs and improve patient outcomes. This development is expected to enhance Accutar’s position in the global oncology market and contribute to the advancement of personalized medicine.-Fineline Info & Tech
